Landgren has published over 250 peer-reviewed publications and he is a frequently invited speaker at national and international hematology conferences. As part of his ongoing research program, he is studying molecular mechanisms underlying the trajectory from precursor to full-blown multiple myeloma with the goal to develop treatment strategies aiming to delay, prevent, and ultimately define a cure for multiple myeloma. Landgren has designed and led the definitive study showing that all multiple myeloma patients are preceded by a precursor stage. Landgren leads the Experimental Therapeutics Program to discover new treatment paradigms for multiple myeloma integrating modern therapy and novel MRD assays. As Chief of the Myeloma program at Chief of Myeloma Program at Sylvester Comprehensive Cancer Center, University of Miami, Dr. Landgren is one of the world leaders in the field of early treatment strategies and molecular- and cell-based monitoring of minimal residual disease (MRD) detection in multiple myeloma and its precursor states. He is a Doris Duke Distinguished Clinical Research Scientist and American Cancer Society Clinical Research Professor.ĭr. Anderson is the Kraft Family Professor of Medicine at Harvard Medical School as well as Director of the Jerome Lipper Multiple Myeloma Center and Lebow Institute for Myeloma Therapeutics at Dana-Farber Cancer Institute. He is a member of the Institute of Medicine of the National Academy of Sciences, served as President of the International Myeloma Society, and is President-elect of the American Society of Hematology. Burchenal Award and the American Cancer Society Medal of Honor in Science.
Kyle Lifetime Achievement Award the American Association for Cancer Research Joseph H. He is a recipient of many scientific and humanitarian awards including: the International Myeloma Workshop Waldenstrom’s Award the International Myeloma Foundation Robert A.
His paradigm for identifying and validating targets in the tumor cell and its milieu has transformed myeloma therapy and markedly improved patient outcome. He has developed laboratory and animal models of the tumor in its microenvironment which have allowed for both identification of novel targets and validation of novel targeted therapies, and has then rapidly translated these studies to clinical trials culminating in FDA approval of novel targeted therapies. Anderson is an internationally recognized researcher on multiple myeloma, the focus of his laboratory and clinical research studies over the last three decades.
0 kommentar(er)
